Thyroid Cancer Diagnostics Market By Test Type (Imaging, Cytology & Histology, Molecular Diagnostics, Blood-based Biomarkers), By Cancer Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma), By Offering (Instruments, Reagents & Consumables, Software & Analytics, Services), By Technology (PCR, Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In Situ Hybridization (FISH, ISH), Ultrasound & Elastography, Nuclear Medicine Imaging), By Application (Screening & Early Detection, Diagnosis & Risk Stratification, Therapy Selection & Companion Diagnostics, Post-Treatment Monitoring & Recurrence Detection, Prognosis & Disease Management, Others), and By End-User (Hospitals & Academic Medical Centers, Diagnostic & Reference Laboratories, Specialty Endocrinology & Oncology Clinics, Radiology & Nuclear Medicine Centers, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2025 – 2035

---

What trends will shape the Thyroid Cancer Diagnostics Market in the coming years?

The Thyroid Cancer Diagnostics Market accounted for USD 3.09 Billion in 2024 and USD 3.27 Billion in 2025 is expected to reach USD 5.81 Billion by 2035, growing at a CAGR of around 5.91% between 2025 and 2035. The thyroid cancer diagnostics market will be driven by a number of major trends in the foreseeable future. Overall, molecular diagnostics and the ability to test for mutations, including BRAF, RET, and NTRK, through the use of NGS panels, are leading to more accuracy and precision for molecular medicine. How liquid biopsy is expected to catch on for monitoring minimal residual disease (MRD) and detection of recurrence. With more effective tools, including AI-enabled digital pathology and ultrasound, early diagnosis will be strengthened and inter-observer bias reduced.

Non-invasive and cost-effective diagnostic solutions will also be in higher demand as health systems look to operate efficiently. Targeted therapies for advanced thyroid cancers will benefit from the ever-increasing use of companion diagnostics. Telepathology and remote diagnostics will make expertise available to a wider market, particularly in emerging markets. An increase in the incidence of thyroid cancer, along with government screening programs, is expected to support the growth of the market. Finally, as brands become more portable and habitualized, industry players will innovate and collaborate on developing more personalized, value-based diagnostics.

What do industry experts say about the Thyroid Cancer Diagnostics market trends?

“AI will be pervasive in health care… in five or ten years, the vast majority of decisions and interactions will be significantly influenced by AI, because it's just too efficient a technology and it's kind of perfectly designed for health care.”

• Eric Lefkofsky, CEO of Tempus.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Thyroid Cancer Diagnostics market?

How is rising thyroid cancer incidence globally driving the adoption of advanced diagnostic technologies?

With the global incidence of thyroid cancer on the steady rise, with data according to the U.S. SEER program reporting an estimated 44,020 new cases in 2025 alone, the adoption of advanced diagnostic technologies is gaining momentum in the Thyroid Cancer Diagnostics Market. "Given the increasing burden of the disease, the need for precise, early, and minimally invasive diagnostic tools to effectively manage patients is acute." High-resolution ultrasound and elastography are becoming common tools to diagnose thyroid nodules with improved accuracy. Molecular diagnostics, such as next-generation sequencing, have improved ways to stratify risk and individualize treatment plans. Fine-needle aspiration with digital pathology (FNA-DP) backed by artificial intelligence (AI) is decreasing indeterminate results and increasing clinician diagnostic confidence.

Blood-based liquid biopsy and blood-based biomarkers are gaining momentum for non-invasive detection and monitoring of recurrence. The increasing patient population also forces healthcare providers to extend telemedicine and remote diagnosis for timely interventions. Diagnostic labs and hospitals are turning to integrated imaging, cytology, and genomics platforms for effective evaluation. Therefore, not only are these innovations leading to better clinical outcomes, but they are also reducing unnecessary operations and healthcare costs. Overall, the increase in thyroid cancer is driving innovation and large-scale deployment of cutting-edge diagnostic technologies worldwide.

Why does growing preference for precision medicine accelerate demand for thyroid cancer diagnostics solutions?

The need for the Thyroid Cancer Diagnostics Market is expected to see exponential growth as precision medicine is becoming increasingly integrated into the management of thyroid cancer cases to provide more effective and targeted solutions to patients. Nearly two in three thyroid cancers are diagnosed in their localized stage, where precision-guided diagnostic tools can play an important role in customizing treatment, according to the Surveillance, Epidemiology, and End Results (SEER) Program. Discovery efforts that will likely lead to targeted treatments. Among thyroid cancers, precision medicine has permitted classifying the disease more correctly based on molecular signatures (BRAF, RET/PTC, and RAS mutations), thus driving the choice in choosing the right therapy for each patient, resulting in better results. This approach not only eliminates the concern of overtreatment for low-risk patients but also ensures that the most robust targeted therapies are being used for high-risk cases.

The development of next-generation sequencing and molecular tests has allowed for a greater understanding of the biology of tumors and is the basis for more individually targeted treatment strategies. As increasing numbers of biomarkers are being identified and studied, the era of companion diagnostics has gradually become the standard of care in thyroid malignancy. It's exactly calibrated to a patient's levels of their genetic makeup, which translates into fewer side effects and a longer survival time. Precision medicine has the potential to address both of these problems at the same time, as the combination of systems-level efficiency and patient-centric care provides a powerful motivating force for medical practitioners to see intelligent diagnostics as a way to increase efficiency and reduce unnecessary interventions. Overall, the trend towards a more individualized management strategy guiding the diagnostic algorithm of thyroid malignancy is truly on the rise globally.

How do high diagnostic procedure costs limit accessibility for patients in emerging global economies?

Tremendous growth is being witnessed in the thyroid cancer diagnostics market by virtue of AI-based systems for diagnosis, thereby markedly increasing the accuracy globally. AI ultrasound models have shown a pooled ultrasound sensitivity of 88% and specificity of 81% with an area under the curve of 0.92, evidencing that this technology could reliably differentiate benign from malignant thyroid nodules. These systems are proving particularly useful in assisting less-experienced clinicians by reducing human variability and decreasing the frequency of unnecessary biopsies far greater than the images alone can.

Recently, advanced multimodality AI solutions that integrate radiomics, deep learning, and TI-RADS can reach remarkable malignancy prediction accuracy of up to 98.7% and provide genetic markers like the BRAF mutations. Such technologies help clinicians risk-stratify and target opportunities for appropriate treatment choices. Image interpretation through automation results in reduced diagnostic delays and improved outcomes for patients. Additionally, AI technologies standardize the process of diagnostics by providing consistent and repeatable outcomes across various healthcare facilities. In emerging markets, AI is stepping in to fill a huge void created by a lack of highly trained radiologists. With the help of AI, the way thyroid cancer is diagnosed is evolving, making it more accessible and reliable all over the world. But ultimately, its integration is allowing for earlier interventions, more effective patient management, and a more equitable health system.

How can the integration of artificial intelligence enhance accuracy in thyroid cancer diagnostics globally?

There is a severe lack of accessibility for patients in emerging economies worldwide due to high costs for diagnostic procedures in frankly poor infrastructures, where access to health care and insurance are not commonly practiced. New diagnostic methods for thyroid cancer, including molecular tests, NGS, imaging techniques, and others, have high equipment/capital costs along with high consumable costs that limit their accessibility for both hospitals and patients. Healthcare spending in many low- and middle-income countries is dominated by out-of-pocket payments, meaning patients have to put off or forego important testing. Unfortunately, this monetary burden often means delayed diagnoses with increasing complexity and decreasing efficacy.

Another reason for the inability to implement these newer diagnostic strategies is the lack of reimbursement for them by the limited government. Others living in rural areas and/or who are underserved face additional barriers because they have no affordable access to testing facilities. As a result, access to early detection and optimal management improves in the developed world and widens between developed and developing markets. Even when there are more sophisticated tests for the condition, their expensive nature means that there is little motivation for their use in large patient groups. This disparity leads to an economic reliance on more traditional diagnostic procedures with potentially less specific sensitivities that limit the ability for disease surveillance. Overall, diagnostic procedures remain prohibitively expensive, and this represents a significant barrier to an equitable thyroid cancer care model in developing regions.

Why will the expansion of molecular biomarkers create significant opportunities in the thyroid cancer diagnostics market?

Molecular biomarkers are emerging as key precision diagnostics tools for diagnosis and patient management, offering enormous chances for growth across the Thyroid Cancer Diagnostics Market. It has a high sensitivity of up to 86% and is an incredibly sensitive biomarker for malignant pathological disease, as the BRAF V600E mutation is present in at least 86% of cases of papillary thyroid carcinoma and not present in benign thyroid nodules or other thyroid cancers. This genetic marker accurately stratifies malignant vs. benign conditions, which will reduce unnecessary surgeries and incorrect diagnoses. In addition to BRAF, other mutations, including RAS, RET/PTC rearrangements, and PAX8/PPARg fusions, are responsible for increasing diagnostic clarity significantly for follicular thyroid and poorly differentiated thyroid cancers.

With the availability of such biomarkers, multigene panels or next-generation sequencing assays can be developed that provide improved accuracy in indeterminate cases. We are already starting to see personalization based on molecular insights being used to select patients for targeted treatments or active monitoring. Their adoption in clinical practice also helps the doctor choose the intensity of surgery and follow-up relevance after the procedure. With increasing adoption of molecular biomarkers, they are closing the gaps between cytology, imaging, and genetic profiling to deliver a more complete line of diagnostic services. Vendor partnerships and collaborations: To meet this increased demand for precision diagnostics, partnerships between biotech companies, diagnostic labs, and healthcare providers are flourishing. Overall, the impact of molecular biomarkers on thyroid cancer diagnosis is revolutionizing healthcare systems around the world, facilitating precision, individualized therapies, and driving advancements in thyroid cancer management.

What are the key market segments in the Thyroid Cancer Diagnostics industry?

Based on the test type, the Thyroid Cancer Diagnostics Market is classified into Imaging, Cytology & Histology, Molecular Diagnostics, and Blood-based Biomarkers. In this setting, ultrasound, CT, and nuclear scans are commonly used for initial screening and tumor localization. Cytology and histology evaluated by fine needle aspiration biopsy (FNAB) are the ideal gold standard for malignancy confirmation and tumor morphology evaluation. Using molecular technologies can give us more information about genetic aberrations, such as BRAF and RAS, for precision medicine and targeted treatments.

Serum-based biomarkers (thyroglobulin, calcitonin) are handy for noninvasive follow-up, posttreatment monitoring, and recurrence. By combining these tests, you obtain a comprehensive evaluation for screening, diagnosis, prognosis, and disease monitoring. These two entities complement each other and represent a multi-modal diagnostic approach to thyroid cancer. This categorization reflects an increasing pressure to combine classical pathology with state-of-the-art molecular and biomarker-based methods.

Based on the application, the Thyroid Cancer Diagnostics Market is classified into Screening & Early Detection, Diagnosis & Risk Stratification, Therapy Selection & Companion Diagnostics, Post-Treatment Monitoring & Recurrence Detection, Prognosis & Disease Management, and Others. It is segmented as follows: early detection & diagnosis screening focuses on identifying high-risk individuals in an early stage to optimize outcomes. Classification of T-ALL subtypes with respect to aggressiveness and prognostication for an appropriate treatment plan.

Therapy selection & companion diagnostics that focus on targeting therapies to patients based on their genetic makeup. Following treatment, there is ongoing monitoring to exclude any possibility of the recurrence of the disease. Prognosis and disease management (PDM) offer potential for improving clinical decision-making by allowing clinicians to more readily predict disease course and modify long-term management. Others refer to supporting and experimental diagnostic methods in addition to conventional methods. Together, these applications provide examples of how diagnostics are essential at every step of the care continuum for thyroid cancer.

Which regions are leading the Thyroid Cancer Diagnostics market, and why?

The North American Thyroid Cancer Diagnostics Market is leading due to the owing to the high prevalence of the disease, advanced healthcare systems, and early adoption of emerging technologies in the region. Successful public health educational and outreach efforts will increase awareness and stimulate demand for early detection. Ecosystem of Diagnostic Laboratories and Academic Centers. The strong network of diagnostic laboratories, academic institutions, and clinical research centers is fueling innovation in the area of molecular testing, artificial intelligence-based imaging, and digital pathology. Sophisticated assays and imaging tools are accessible to patients through an appropriate reimbursement system and insurance coverage.

The region is dominated by the United States, whose extensive healthcare expenditure and fast adoption of new diagnostic platforms have been catalytic in putting in place screening tests and consequent treatment interventions. Highly competitive R&D expenditure, Proper investments by the leading industry players ensure that technological innovation is maintained. Networking between healthcare providers, scientific research organizations, and diagnostic enterprises has a positive impact on the innovation and commercialization process. North America is the region most influential in the development of global diagnostic practices for thyroid cancer due to infrastructure and policy support, and technological leadership.

The Asia Pacific Thyroid Cancer Diagnostics Market is growing due to the increasing incidence of thyroid cancer and the modernization of the regional healthcare system. Population explosions in some other countries, including China, India, South Korea, and Japan, are generating robust demand for early detection and molecular testing. Governments in various Asian countries are initiating programs to improve the diagnosis of cancer and increase the availability of screening, especially in urban and rural areas. With the increase in awareness of mental health issues, funding is growing to support the infrastructure required for diagnosis, such as facilities with laboratories and imaging.

Increasing adoption of next-generation sequencing with artificial intelligence (AI)-based diagnostic tools from countries with high technological maturity is driving regional growth. Purchasing power, disposable income, insurance reform, and convenience. These geographies are where biotechnology and service delivery companies are innovating through consortia with research institutions and healthcare providers. Overall, due to size, modernization, and a favorable policy environment in the region, the rate of thyroid cancer diagnosis is growing, making Asia the fastest-growing market in the world.

What does the competitive landscape of the Thyroid Cancer Diagnostics market look like?

The Thyroid Cancer Diagnostics Market witnesses high levels of competition with large players like Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Veracyte, QIAGEN, and Interpace Biosciences, among others, competing to bring innovations in the diagnostic technologies. Organizations are pivoting to combining imaging, molecular diagnostics, and artificial intelligence to increase the accuracy and speed at which detection can occur. In early 2025, to bolster its focus on AI-powered ultrasound solutions, RadNet's DeepHealth acquired See-Mode Technologies, a testament to the increasing embrace of intelligent imaging AI solutions. Also around that time, LisenID formed a strategic partnership with Mayo Clinic to co-develop early cancer diagnostics based on epigenetic imprinting.

Foundation Medicine's plan to magnify fusion detection capabilities in thyroid and other cancers in December 2024 builds on the company's FoundationOne RNA assay swap completion for major precision oncology capabilities. We find many academic corpora as well, an example being this from the University of Hong Kong, where an AI model was created to categorize the risk of thyroid cancer with an accuracy of 90%. The picture above suggests a growing focus on personalized medicine and higher levels of biomarker research. Technological advances in digital pathology and next-generation sequencing are also driving savings for their use in providing an integrated diagnosis solution. Mezzanine & mezzanine preliminaries, arrangements, and association pipelines stay key drivers of aggressive systems of action. Altogether, these developments are redefining the market by allowing an earlier diagnosis, improved prognosis, and optimized and streamlined treatment courses.

Thyroid Cancer Diagnostics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Thyroid Cancer Diagnostics industry?

• In July 2025, Interpace Diagnostics expanded its molecular test portfolio by acquiring assays for thyroid and pancreatic cancers, strengthening its role in precision diagnostics.
• In June 2025, RadNet’s subsidiary DeepHealth acquired See-Mode Technologies to enhance AI-powered ultrasound imaging capabilities in cancer diagnostics.
• In June 2025, the pharmaceutical company ESTEVE acquired the global rights to Caprelsa® (vandetanib), a targeted therapy for symptomatic medullary thyroid cancer, from Sanofi. This transaction, announced on June 30, 2025, includes rights in over 50 countries and marks a significant step in ESTEVE's strategic focus on highly specialized treatments for significant unmet medical needs.

Report Coverage:

By Test Type

• Imaging
• Cytology & Histology
• Molecular Diagnostics
• Blood-based Biomarkers

By Cancer Type

• Papillary Thyroid Cancer
• Follicular Thyroid Cancer
• Medullary Thyroid Cancer
• Anaplastic Thyroid Cancer
• Poorly Differentiated Thyroid Carcinoma

By Offering

• Instruments
• Reagents & Consumables
• Software & Analytics
• Services

By Technology

• PCR
• Next-Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• In Situ Hybridization (FISH, ISH)
• Ultrasound & Elastography
• Nuclear Medicine Imaging

By Application

• Screening & Early Detection
• Diagnosis & Risk Stratification
• Therapy Selection & Companion Diagnostics
• Post-Treatment Monitoring & Recurrence Detection
• Prognosis & Disease Management
• Others

By End-User

• Hospitals & Academic Medical Centers
• Diagnostic & Reference Laboratories
• Specialty Endocrinology & Oncology Clinics
• Radiology & Nuclear Medicine Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• General Electric Company
• Agilent Technologies Inc.
• Illumina Inc.
• QIAGEN N.V.
• Bio-Rad Laboratories Inc.
• Beckman Coulter Inc.
• Veracyte Inc.
• Interpace Biosciences Inc.
• Myriad Genetics Inc.
• Guardant Health Inc.

Frequently Asked Questions (FAQs)